A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

Inclusion Criteria: * A documented history of non-infectious intermediate, anterior and intermediate, posterior or panuveitis. * Minimum prescribed therapy upon enrollment is one or more of the following: * systemic prednisone or equivalent averaging ≥ 10 mg/day * at least 2 periocular/intravitreal corticosteroid administrations for control of inflammatory disease within the previous 8 months (but not within 6 weeks of randomization). * at least one, but not more than 2 immunosuppressive drugs from among the following compounds: cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, methotrexate * Subjects with clinically quiescent uveitis in both eyes at enrollment and who have been on a stable treatment regimen for a minimum of 6 weeks * Best-corrected distance visual acuity in the worst involved eye of 20/400 or better (ETDRS logMAR \<1.34) * Subjects not planning to undergo elective ocular surgery during the study Exclusion Criteria: * Evidence of active, uncontrolled non-infectious uveitis * Periocular administration of corticosteroids within the previous 6 weeks. * Uveitis of infectious etiology * Uncontrolled glaucoma * Clinically suspected or confirmed central nervous system or ocular lymphoma * History or diagnosis of Behçet's disease * Primary diagnosis of anterior uveitis